key: cord-0784026-3wwkmvao
authors: Neuman, Benjamin W.; Stein, David A.; Kroeker, Andrew D.; Bestwick, Richard K.; Iversen, Patrick L.; Moulton, Hong M.; Buchmeier, Michael J.
title: Inhibition and Escape of SARS-CoV Treated with Antisense Morpholino Oligomers
date: 2006
journal: The Nidoviruses
DOI: 10.1007/978-0-387-33012-9_103
sha: b904094b2f44f96a67a33ceff2808c1db9a3f030
doc_id: 784026
cord_uid: 3wwkmvao

nan

Identification of potential SARS-CoV antiviral compounds has progressed swiftly, thanks in part to the availability of bioinformatic and virus structural data. Antivirals that target the SARS-CoV superfamily 1 helicase and the 3C-related serine proteinase with low micromolar EC 50 values have been reported. [1] [2] [3] The papain-related cysteine proteinase may prove to be an unsuitable target, as a coronavirus molecular clone lacking one of the two known cleavage sites for this enzyme displayed only minor growth defects in cell culture. 4 Other confirmed and putative viral enzymes including the polymerase, poly(U)specific endo-ribonuclease homolog, S-adenosyl-methionine-dependent ribose 2'-Omethyltransferase, and cyclic phosphodiesterase represent plausible anti-SARS targets. 5 Antivirals targeting the interaction of the viral spike protein with the ACE-2 receptor, 2, 3, 6 or with the spike-mediated fusion event, [7] [8] [9] [10] and showing micromolar-scale efficiency in cell culture, have been reported. Several groups have also reported antiviral in vitro efficacy with siRNAs. 11 The antisense agents directed against single-stranded RNA are known to act by two general mechanisms: by causing damage to an RNA strand containing the complementary "target" sequence through priming of endogenous RNase H activity, or by stably binding to and steric interference with targeted RNA function. Phosphorodiamidate morpholino oligomers (PMO) act by the latter mechanism, duplexing to specific RNA sequence by Watson-Crick base pairing and forming a steric block. 12 The most frequently successful targeting strategies for PMO-based gene knockdown involve interfering with translation initiation 13 or masking splice sites. 14 We recently demonstrated antiviral effects in vitro for one peptide-conjugated PMO (P-PMO) complementary to the AUG translation start site region of a murine coronavirus replicase polyprotein. 15 We reasoned that antiviral effects of P-PMO might be improved by choosing conserved RNA sequence elements and secondary structures critical for replication, transcription, and host factor interaction as targets. In this report, we demonstrate that antisense-mediated suppression of viral replication can be achieved by targeting conserved RNA elements required for viral RNA synthesis and translation.

PMO complementary to the genomic (positive-sense) strand, which were designed to bind regions identified by conservation or noted in the literature as critical for viral RNA synthesis, were synthesized (Fig. 1a) . PMO were covalently linked to peptides NH 2 -RRRRRRRRRFFC-CONH 2 or NH 2 -RRRRRFFRRRRC-CONH 2 designated as R 9 F 2 or R 5 F 2 R 4 , respectively. Both types of peptide-conjugated PMO are henceforth referred to as P-PMO, and were used interchangeably in these studies. Cells treated with 20 µM PMO were at least 80% viable, as measured by MTT viability assay (data not shown).

We tested P-PMO for correlates of antiviral efficacy: reduction of viral titer, rate of spread in vitro, and viral subgenomic RNA load. Vero-E6 cells were pretreated with P-PMO 6 h prior to low multiplicity inoculation, and supernatants were collected for titration 24 h later (Fig. 1b) . The most effective P-PMO (TRS2) decreased viral titers below the threshold of detection in the experiment shown, and reduced peak titers by 10,000-fold in some assays (not shown). TRS1 and TRS2 exhibited robust antiviral activity in the low micromolar range.

We next tested the effectiveness of P-PMO on viral persistence and spread of an established infection by performing plaque-size reduction assays. In this assay, cells were treated with P-PMO 1 h after inoculation with a standardized amount of SARS-CoV. Plaque diameter was measured 72 h after inoculation. The TRS2 P-PMO was most effective at reducing SARS-CoV spread in cell culture (Fig. 1C) . We reasoned that inhibition of viral growth should correspond with a decrease in the viral RNA level, whether through inhibition of replicase expression, interference with discontinuous RNA synthesis at the leader TRS, or an alternate mechanism. Coronaviruses produce a nested set of sub-genome-length RNA species in infected cells. We investigated genomic and subgenomic RNA production 24 h after low-multiplicity inoculation. RT-PCR products specific to each of eight subgenomic RNA species were strongly amplified from untreated cells and cells treated with less effective P-PMO ( Fig. 1D and data not shown) . Equal volumes of RT-PCR products from an equivalent number of infected cells pretreated with 20 µM TRS2 P-PMO were faint (i.e., sgRNA 8 and possibly 9) or undetectable (sgRNA 2-7; Fig. 1D ). Genomic RNA synthesis was likewise qualitatively reduced by 20 µM TRS2 P-PMO (data not shown).

The error-prone replication of RNA viruses presents a rapid model for viral evolution and drug resistance studies. In order to assess the propensity for SARS-CoV to develop resistance to antisense P-PMO, a stock cultured from a plaque-purified biological clone of SARS-CoV was serially passaged on cells pretreated with P-PMO. Viral growth was assessed, after each passage ( Fig. 2A) . Treatment with 10 µM TRS2 P-PMO strongly inhibited SARS-CoV growth for several passages. However, an increase in titer indicative of partial resistance was observed after seven passages. SARS-CoV plaque purified after 11 rounds of TRS2 P-PMO selection formed small plaques on Vero-E6 cells in the absence of P-PMO (Fig. 2B) . TRS2 P-PMO-selected SARS-CoV displayed delayed growth kinetics compared with untreated SARS-CoV and other P-PMO-selected SARS-CoV (data not shown). RNA was isolated from plaque purified SARS-CoV selected after 11 rounds of serial P-PMO treatment. RT-PCR amplicons from 14 serially P-PMO-treated SARS-CoV were sequenced to determine whether the virus had undergone mutation during P-PMO selection. Three contiguous base changes of CTC to AAA at position 61-63, proximal to the leader TRS and within the target region of TRS2-P-PMO, appeared in only the 14 amplicons from TRS2-resistant SARS-CoV (Fig.  2C ).

Thermal melting curve data for peptide-conjugated PMO/RNA duplexes with variable mismatches lead us to speculate that the three mutations at the TRS2-P-PMO target site reduce the effective melting temperature (Tm) by ~25-30ºC (H. Moulton et al., construct in which the luciferase reporter gene was placed immediately downstream of either the wild-type SARS-CoV TRS region or the same region with the CTC AAA mutations observed in TRS2 P-PMO-selected SARS-CoV clones (Fig. 3A) . TRS2 P-PMO was approximately ten-fold less active against the 3-mismatch TRS target compared with the wild-type target (EC 50 of 500nM and 50 nM, respectively). The decreased sensitivity to TRS2 P-PMO was consistent with reduced P-PMO/target RNA duplex stability in partially-TRS2-resistant SARS-CoV. A similar observation was recently reported for HIV-1 escape variants resistant to siRNAs. 17 569 manuscript in preparation and ). P-PMO binding affinity was compared using a reporter 16 Figure 2 . Escape of SARS-CoV after serial P-PMO passage. The titer of infectious SARS-CoV grown over nine rounds of treatment with selected P-PMOs was measured by TCID 50 titration (A). Error bars indicate standard error throughout. Plaque morphology of P-PMO-resistant SARS-CoV strains was assessed in the absence of P-PMO. Mean plaque diameter is shown (B). SARS-CoV strains selected after serial P-PMO treatment were sequenced. The region comprising the TRS2 P-PMO binding site is shown (C). Sequences from untreated and DSCR-treated SARS-CoV represent wild-type sequence, and mutations found in all TRS2selected strains are underlined. Sequence is from the complementary (minus-sense) strand. The antiviral effects of TRS2 P-PMO were consistent with multiple mechanisms of action. In order to determine whether the high efficacy of TRS2 could be attributed to steric blockade of translation, a reporter construct was designed in which luciferase expression was initiated at the AUG codon of the authentic SARS-CoV replicase open reading frame 1a AUG, downstream of the SARS-CoV 5'-untranslated region. TRS2 P-PMO was much more effective than AUG1 P-PMO in inhibiting reporter translation (EC 50 of 35 nM vs. 185 nM ; Fig, 3B ). The TRS2 target site (bases 55-75) is sufficiently distal from both the 5'-terminus and the site of translation initiation to make it unlikely that interference with events of pre-initiation at the terminus (e.g., the 43S complex loading onto mRNA) or initiation at the initiator AUG (e.g., 48S-complex formation and/or joining of 48S and 60S ribosomal subunits) forms the basis for the observed effect. We therefore concluded that TRS2 P-PMO primarily inhibits SARS-CoV growth by interference with translation, perhaps at the 43S-preinitiation complex scanning. 

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics

Small molecules targeting severe acute respiratory syndrome human coronavirus

Cleavage between replicase proteins p28 and p65 of mouse hepatitis virus is not required for virus replication

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus

Interaction between heptad repeat 1 and 2 regions in spike protein of SARSassociated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells

Morpholino antisense oligomers: the case for an RNase H-independent structural type

Effective targeted gene 'knockdown' in zebrafish

Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA

Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth

A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome